Aktiviteetteja vuodessa
Abstrakti
This study aimed to explore the cytochrome P450 (CYP) metabolic and inhibitory profile of hydroxychloroquine (HCQ). Hydroxychloro-quine metabolism was studied using human liver microsomes (HLMs) and recombinant CYP enzymes. The inhibitory effects of HCQ and its metabolites on nine CYPs were also determined in HLMs, us-ing an automated substrate cocktail method. Our metabolism data in-dicated that CYP3A4, CYP2D6, and CYP2C8 are the key enzymes involved in HCQ metabolism. All three CYPs formed the primary me-tabolites desethylchloroquine (DCQ) and desethylhydroxychloro-quine (DHCQ) to various degrees. Although the intrinsic clearance (CLint) value of HCQ depletion by recombinant CYP2D6 was > 10-fold higher than that by CYP3A4 (0.87 versus 0.075 mu l/min/pmol), scaling of recombinant CYP CLint to HLM level resulted in almost equal HLM CLint values for CYP2D6 and CYP3A4 (11 and 14 mu l/min/mg, respec-tively). The scaled HLM CLint of CYP2C8 was 5.7 mu l/min/mg. Data from HLM experiments with CYP-selective inhibitors also suggested rela-tively equal roles for CYP2D6 and CYP3A4 in HCQ metabolism, with a smaller contribution by CYP2C8. In CYP inhibition experiments, HCQ, DCQ, DHCQ, and the secondary metabolite didesethylchloroquine were direct CYP2D6 inhibitors, with 50% inhibitory concentration (IC50) val- ues between 18 and 135 mu M. HCQ did not inhibit other CYPs. Further- more, all metabolites were time-dependent CYP3A inhibitors (IC50 shift 2.2-3.4). To conclude, HCQ is metabolized by CYP3A4, CYP2D6, and CYP2C8 in vitro. HCQ and its metabolites are reversible CYP2D6 inhibi- tors, and HCQ metabolites are time-dependent CYP3A inhibitors. These data can be used to improve physiologically-based pharmacokinetic models and update drug-drug interaction risk estimations for HCQ.
Alkuperäiskieli | englanti |
---|---|
Lehti | Drug Metabolism and Disposition |
Vuosikerta | 51 |
Numero | 3 |
Sivut | 293-305 |
Sivumäärä | 13 |
ISSN | 0090-9556 |
DOI - pysyväislinkit | |
Tila | Julkaistu - 1 maalisk. 2023 |
OKM-julkaisutyyppi | A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä, vertaisarvioitu |
Tieteenalat
- 3121 Yleislääketiede, sisätaudit ja muut kliiniset lääketieteet
- 317 Farmasia
Aktiviteetit
- 1 Suullinen esitys
-
Hydroxychloroquine is metabolized by CYP2D6, CYP3A4 and CYP2C8, and inhibits CYP2D6 in vitro
Paludetto, M.-N. I. A. (Puhuja)
29 marrask. 2021 → 30 marrask. 2021Aktiviteetti: Puhe- tai esitystyypit › Suullinen esitys